Cargando…

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition

PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Mitchell C., Krzyzanski, Wojciech, Chou, James Z., Signore, Pierre E., Fung, Cyra K., Guzman, David, Li, Dongxia, Zhang, Weihua, Olsen, David R., Nguyen, Viet-Tam L., Koo, Carolyn W., Sternlicht, Mark D., Lipson, Kenneth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942499/
https://www.ncbi.nlm.nih.gov/pubmed/27059922
http://dx.doi.org/10.1007/s11095-016-1918-0
_version_ 1782442420355465216
author Brenner, Mitchell C.
Krzyzanski, Wojciech
Chou, James Z.
Signore, Pierre E.
Fung, Cyra K.
Guzman, David
Li, Dongxia
Zhang, Weihua
Olsen, David R.
Nguyen, Viet-Tam L.
Koo, Carolyn W.
Sternlicht, Mark D.
Lipson, Kenneth E.
author_facet Brenner, Mitchell C.
Krzyzanski, Wojciech
Chou, James Z.
Signore, Pierre E.
Fung, Cyra K.
Guzman, David
Li, Dongxia
Zhang, Weihua
Olsen, David R.
Nguyen, Viet-Tam L.
Koo, Carolyn W.
Sternlicht, Mark D.
Lipson, Kenneth E.
author_sort Brenner, Mitchell C.
collection PubMed
description PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and concentrations of these proteins as well as endogenous CTGF were determined by immunoassays. FG-3019, or (125)I-labeled FG-3019, and human CTGF (rhCTGF) were co-administered to assess the impact of CTGF on the elimination rate and tissue localization of FG-3019, which was further characterized by immunohistochemical analysis. A PK/PD model for target-mediated elimination of FG-3019 was developed to fit the kinetic data. RESULTS: FG-3019 exhibited non-linear pharmacokinetics in rats. Circulating concentrations of the N-terminal half of CTGF increased after dosing with FG-3019, reached maximal levels after 1–5 days, and returned toward baseline levels as FG-3019 cleared from the circulation, whereas the concentration of intact CTGF was unaffected by administration of FG-3019. Co-administration of rhCTGF dramatically enhanced the rate of FG-3019 elimination, redistributing the majority of (125)I-labeled FG-3019 from the blood to the liver, kidney, spleen and adrenal gland. FG-3019 co-administered with CTGF was found along the sinusoids of the liver and adrenal glands, the capillaries of the kidney glomeruli and in the spleen. A pharmacokinetic model for target-mediated elimination of FG-3019 was used to fit the time courses of FG-3019 and endogenous CTGF plasma concentrations, as well as time courses of rhCTGF and rhCTGF N-fragment after intravenous administration of these species. CONCLUSIONS: FG-3019 is subject to target mediated elimination in rats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11095-016-1918-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4942499
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-49424992016-07-26 FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition Brenner, Mitchell C. Krzyzanski, Wojciech Chou, James Z. Signore, Pierre E. Fung, Cyra K. Guzman, David Li, Dongxia Zhang, Weihua Olsen, David R. Nguyen, Viet-Tam L. Koo, Carolyn W. Sternlicht, Mark D. Lipson, Kenneth E. Pharm Res Research Paper PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and concentrations of these proteins as well as endogenous CTGF were determined by immunoassays. FG-3019, or (125)I-labeled FG-3019, and human CTGF (rhCTGF) were co-administered to assess the impact of CTGF on the elimination rate and tissue localization of FG-3019, which was further characterized by immunohistochemical analysis. A PK/PD model for target-mediated elimination of FG-3019 was developed to fit the kinetic data. RESULTS: FG-3019 exhibited non-linear pharmacokinetics in rats. Circulating concentrations of the N-terminal half of CTGF increased after dosing with FG-3019, reached maximal levels after 1–5 days, and returned toward baseline levels as FG-3019 cleared from the circulation, whereas the concentration of intact CTGF was unaffected by administration of FG-3019. Co-administration of rhCTGF dramatically enhanced the rate of FG-3019 elimination, redistributing the majority of (125)I-labeled FG-3019 from the blood to the liver, kidney, spleen and adrenal gland. FG-3019 co-administered with CTGF was found along the sinusoids of the liver and adrenal glands, the capillaries of the kidney glomeruli and in the spleen. A pharmacokinetic model for target-mediated elimination of FG-3019 was used to fit the time courses of FG-3019 and endogenous CTGF plasma concentrations, as well as time courses of rhCTGF and rhCTGF N-fragment after intravenous administration of these species. CONCLUSIONS: FG-3019 is subject to target mediated elimination in rats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11095-016-1918-0) contains supplementary material, which is available to authorized users. Springer US 2016-04-08 2016 /pmc/articles/PMC4942499/ /pubmed/27059922 http://dx.doi.org/10.1007/s11095-016-1918-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Paper
Brenner, Mitchell C.
Krzyzanski, Wojciech
Chou, James Z.
Signore, Pierre E.
Fung, Cyra K.
Guzman, David
Li, Dongxia
Zhang, Weihua
Olsen, David R.
Nguyen, Viet-Tam L.
Koo, Carolyn W.
Sternlicht, Mark D.
Lipson, Kenneth E.
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title_full FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title_fullStr FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title_full_unstemmed FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title_short FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
title_sort fg-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942499/
https://www.ncbi.nlm.nih.gov/pubmed/27059922
http://dx.doi.org/10.1007/s11095-016-1918-0
work_keys_str_mv AT brennermitchellc fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT krzyzanskiwojciech fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT choujamesz fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT signorepierree fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT fungcyrak fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT guzmandavid fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT lidongxia fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT zhangweihua fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT olsendavidr fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT nguyenviettaml fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT koocarolynw fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT sternlichtmarkd fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition
AT lipsonkennethe fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition